3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
13
Terminated
8
Active not recruiting
2
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Hematologic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Leukemia, Myeloid, Acute
3
beta-Thalassemia
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Graft vs Host Disease
2
Anemia, Refractory, with Excess of Blasts
2
Virus Diseases
1
Thalassemia
1
Primary Myelofibrosis
1
Non-Malignant Neoplasm
1
Neurofibromatosis 1
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, B-Cell
1
Influenza, Human
1
Fanconi Anemia
1
Cytopenia
1
Chromosome Aberrations
1
Chromosome 7, monosomy
1
Anemia, Sickle Cell
1
Interventions
asciminib
10
Cyclophosphamide
9
Mycophenolic Acid
7
fludarabine
5
Whole-Body Irradiation
5
nilotinib
4
fludarabine phosphate
4
Stem Cell Transplantation
4
Specimen Handling
4
Dasatinib
4
olverembatinib
3
bosutinib
3
Imatinib Mesylate
3
Cyclosporine
3
venetoclax
2
ponatinib
2
blinatumomab
2
X-Rays
2
Thiotepa
2
Tacrolimus
2
Sirolimus
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Hematopoietic Stem Cell Transplantation
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Cyclosporins
2
Bone Marrow Transplantation
2
Blood Component Removal
2
Biopsy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
thymoglobulin
×
Clear all
NCT04888741
2026-05-05
MoTD
University of Birmingham
Phase 2
Recruiting
400 enrolled